Matthew Wongchenko

Matthew Wongchenko

UNVERIFIED PROFILE

Are you Matthew Wongchenko?   Register this Author

Register author
Matthew Wongchenko

Matthew Wongchenko

Publications by authors named "Matthew Wongchenko"

Are you Matthew Wongchenko?   Register this Author

24Publications

799Reads

14Profile Views

The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs.

Life Sci Alliance 2019 08 28;2(4). Epub 2019 Jun 28.

Charité-Universitätsmedizin, Institute of Pathology, Berlin, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26508/lsa.201900445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600015PMC
August 2019

Robust network inference using response logic.

Bioinformatics 2019 Jul;35(14):i634-i642

Institut für Pathologie, Charité-Universitätsmedizin, Berlin.

View Article

Download full-text PDF

Source
https://academic.oup.com/bioinformatics/article/35/14/i634/5
Publisher Site
http://dx.doi.org/10.1093/bioinformatics/btz326DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612863PMC
July 2019

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS.

Lancet Oncol 2017 11 31;18(11):e638. Epub 2017 Oct 31.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30785-4DOI Listing
November 2017

HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin.

Mol Cell Biol 2015 Apr 2;35(8):1390-400. Epub 2015 Feb 2.

Department of Discovery Oncology, Genentech, Inc., South San Francisco, California, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.01307-14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372692PMC
April 2015

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Clin Cancer Res 2013 Dec 18;19(24):6976-86. Epub 2013 Oct 18.

Authors' Affiliations: Oncology Biomarker Development, Portfolio Management and Operations, Translational Oncology, Biostatistics, and Exploratory Clinical Development, Genentech Inc., DNA Way, South San Francisco, California; Experimental Therapeutics, Molecular Pathology, Breast Cancer and Melanoma, Gastrointestinal and Endocrine Tumors Groups, and Medical Oncology Service, Vall d'Hebron Institute of Oncology, Barcelona; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain; and Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0978DOI Listing
December 2013